Steroid sulfatase inhibitors

Medicinal Research Reviews

Volumn 24, Issue 4, 2004, Pages 529-576

  Nussbaumer, Peter ^a   Billich, Andreas ^a  

^a Novartis Inst BioMed Res Vienna   (Austria)

Author keywords

Arylsulfatase; Breast cancer; Steroid sulfatase; Sulfamate

Indexed keywords

4 HYDROXYTAMOXIFEN; ANDROGEN; DANAZOL; ENZYME INHIBITOR; ESTROGEN; HYDROXYSTEROID; KAEMPFEROL; MEDROGESTONE; MEDROXYPROGESTERONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NARINGENIN; NOMEGESTROL ACETATE; NORELGESTROMIN; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROMEGESTONE; QUERCETIN; STEROID SULFATASE INHIBITOR; STERYL SULFATASE; SULFATE; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG;

ACNE; BREAST CANCER; DRUG INDICATION; DRUG POTENCY; DRUG STRUCTURE; ENDOMETRIUM CANCER; ENZYME MECHANISM; HUMAN; HUMAN CELL; HYDROLYSIS; MALE TYPE ALOPECIA; PROSTATE CANCER; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; X RAY;

BINDING SITES; ENZYME INHIBITORS; HUMANS; STERYL-SULFATASE;

EID: 3042654981     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20008     Document Type: Review

References (203)

1. Parenti G, Meroni G, Ballabio A. The sulfatase gene family. Curr Opin Genet Dev 1997;7:386-391.
2. Urbitsch P, Salzer MJ, Hirschmann P, Vogt PH. Arylsulfatase D gene in Xp22.3 encodes two protein isoforms. DNA Cell Biol 2000;19:765-773.
3. Ferrante P, Messali S, Meroni G, Ballabio A. Molecular and biochemical characterisation of a novel sulphatase gene: Arylsulfatase G (ARSG). Eur J Hum Genet 2002;10:813-818.
4. Kolodny EH, Fluharty AL. Metachromic leukodystrophy and multiple sulfatase deficiency. Sulfate lipidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995. pp 2693-2741.
5. Matalon R, Arbogast B, Dorfman A. Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maoteaux-Lamy syndrome. Biochem Biophys Res Commun 1974;61:1450-1457.
6. O'Brien JF, Cantz M, Sprangier J. Maroteaux-Lamy disease (mucopoly-saccharidosis VI), subtype A: Deficiency of N-acetylgalactosamine 4-sulfate. Biochem Biophys Res Commun 1974;60:1170-1177.
7. Chang PL, Mueller OT, Lafrenie RM, Varey PA, Rosa NE, Davidson RG, Henry WM, Shows TB. The human arylsulfatase-C isoenzymes. Two distinct genes that escape from X inactivation. Am J Hum Genet 1990;46:729-737.
8. Franco B, Meroni G, Parenti G, Levilliers J, Bernard L, Gebbia M, Cox L, Maroteaux P, Sheffield L, Rappold GA, Andria G, Petit C, Ballabio A. A cluster of sulfatase genes on Xq22.3: Mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell 1995;81:15-25.
9. Puca AA, Zollo M, Repetto M, Andolfi G, Guffanti A, Simon G, Ballabio A, Franco B. Identification by shotgun sequencing, genomic organization, and functional analysis of a fourth arylsulfatase gene (ARSF) from the Xp22.3 region. Genomics 1997;42:192-199.
10. Daniele A, Parenti G, d'Addio M, Andria G, Ballabio A, Meroni G. Biochemical characterization of arylsulfatase E and functional analysis of mutations found in patients with X-linked chondrodysplasia punctata. Am J Hum Genet 1998;62:562-572.
11. Roy AB. The hydrolysis of sulfate esters. In: Boyer PD, editor. The enzymes. New York: Academic Press; 1971. pp 2-19.
12. Daniel WL. Arylsulfatase C and the steroid sulfatases. Isozymes Curr Top Biol Med Red 1985;12:189-228.
13. Dibbelt L, Kuss E. Human placental sterylsulfatase. Biol Chem Hoppe-Seyler 1991;372:173-185.
14. Norkowska M, Gniot-Szulzycka J. Sterolsulphate sulphohydrolase from human placenta microsomes-30 kDa molecular weight form of cholesterol sulphate sulphohydrolase. J Steroid Biochem Mol Biol 2002;81:263-271.
15. Conary J, Nauerth A, Burns G, Hasilik A, von Figura K. Steroid sulfatase. Biosynthesis and processing in normal and mutant fibroblasts. Eur J Biochem 1986;158:71-76.
16. Dibbelt L, Kuss E. Human placental steryl-sulfatase. Enzyme purification, production of antisera, and immunoblotting reactions with normal and sulfatase-deficient placentas. Biol Chem Hoppe Seyler 1986;367:1223-1229.
17. Vaccaro AM, Salvioli R, Muscillo M, Renola L. Purification and properties of arylsulfatase C from human placenta. Enzyme 1987;37:115-126.
18. Noel H, Plante L, Bleau G, Chapdelaine A, Roberts KD. Human placental steroid sulfatase: Purification and properties. J Steroid Biochem 1983;19:1591-1598.
19. Burns GRJ. Purification and partial characterization of arylsulphatase C from human placental microsomes. Biochim Biophys Acta 1983;759:199-204.
20. van der Loos CM, van Breda AJ, van den Berg FM, Walboomers JM, Jobsis AC. Human placental steroid sulphatase-Purification and monospecific antibody production in rabbits. J Inherit Metab Dis 1984;7:97-103.
21. Suzuki T, Hirato K, Yanaihara T, Kadofuku T, Sato T, Hoshino M, Yanaihara N. Purification and properties of steroid sulfatase from human placenta. Endocrinol Japon 1992;39:93-101.
22. Hernandez-Guzman FG, Higashiyama T, Osawa Y, Ghosh D. Purification, characterization and crystallization of human placental estrone/ dehydroepiandrosterone sulfatase, a membrane-bound enzyme of the endoplasmic reticulum. J Steroid Biochem Mol Biol 2001;78:441-450.
23. Hernandez-Guzman FG, Higashiyama T, Pangborn W, Osawa Y, Ghosh D. Structure of human estrone sulfatase suggests functional roles of membrane association. J Biol Chem 2003;278:22989-22997.
24. Stein C, Hille A, Seidel J, Rijnbout S, Waheed A, Schmidt B, Geuze H, von Figura K. Cloning and expression of human steroid-sulfatase. J Biol Chem 1989;264:13865-13872.
25. Willemsen R, Kroos M, Hoogeveen AT, van Dongen JM, Parenti G, van der Loos CM, Reuser AJ. Ultrastructural localization of steroid sulphatase in cultured human fibrobalsts by immunocytchemistry. A comparative study with lysosomal enzymes and the mannose 6-phosphate receptor. Histochem J 1988;20:41-51.
26. Dooley TP, Haldeman-Cahill R, Joiner J, Wilborn TW. Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem Biophys Res Commun 2000;277:236-245.
27. 4 isomerase (3β-HSD), 17β-HSD, 5α-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 1994;104:103-111.
28. Miki Y, Nakata T, Suzuki T, Damel AD, Moriya T, Kaneko C, Hidaka K, Shiotsu Y, Kusaka H, Sasano H. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab 2002;87:5760-5768.
29. Gniot-Szulzycka J, Drywa A. A "soluble" form of sterol sulphate sulphohydrolase from cell nuclei of human placenta tissue-Examinations with oestrone sulphate as substrate. J Steroid Biochem Molec Biol 1994;49:195-201.
30. Zhu BT, Fu JH, Xu S, Kauffman FC, Conney AH. Different biochemical properties of nuclear and microsomal estrone-3-sulfatases: Evidence for the presence of a nuclear isozyme. Biochem Biophys Res Commun 1998;246:45-49.
31. Kauffman FC, Sharp S, Allan BB, Burchell A, Coughtrie MW. Microsomal steroid sulfatase: Interactions with cytosolic steroid sulfotransferases. Chem Biol Interact 1998;109:169-182.
32. Lukatela G, Krauss N, Theis K, Selmer T, Gieselmann V, von Figura K, Saenger W. Crystal structure of human arylsulfatase A: The aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. Biochemistry 1998;37:3564-3664.
33. Bond SC, Clements PR, Ashby SJ, Collyer CA, Harrop SJ, Hopwood JJ, Guss JM. Structure of a human lysosomal sulfatase. Structure 1997;5:277-289.
34. Schmidt B, Selmer T, Ingendoh A, von Figura K. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 1995;82:271-278.
35. Dierks T, Schmidt B, von Figura K. Conversion of cysteine to formylglycine: A protein modification in the endoplasmatic reticulum. Proc Natl Acad Sci USA 1997;94:11963-11968.
36. Recksiek M, Selmer T, Dierks T, Schmidt B, von Figura K. Sulfatases, trapping of the sulfated enzyme intermediate by substituting the active site formylglycine. J Biol Chem 1998;273:6096-6103.
37. Knaust A, Schmidt B, Dierks T, von Bulow R, von Figura K. Residues critical for formylglycine formation and/or catalytic activity of arylsulfatase A. Biochemistry 1998;37:13941-13946.
38. von Bülow R, Schmidt B, Dierks T, von Figura K, Usón I. Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis. J Mol Biol 2001;305:269-277.
39. Uhlhorn-Dierks G, Kolter T, Sandhoff K. How does nature cleave sulfuric acid esters? A novel posttranslational modification of sulfatases. Angew Chem (Int Ed) 1998;37:2453-2455.
40. Purohit A, Williams GJ, Howarth NM, Potter BVL, Reed MJ. Inactivation of steroid sulfatase by an active site directed inhibitor, estrone 3-O-sulfamate. Biochemistry 1995;34:11508-11514.
41. Howarth NM, Purohit A, Robinson JJ, Vicker N, Reed MJ, Potter BV. Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity. Homology model construction and docking studies. Biochemistry 2002;41:14801-14814.
42. Ballabio A, Shapiro LJ. Steroid sulfatase deficiency and X-linked ichthyosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995. pp 2999-3022.
43. Hernández-Martín A, González-Sarmiento R, De Unamuno P. X-linked ichthyosis. Br J Dermatol 1999;141:617-627.
44. Williams ML, Elias PM. Stratum comeum lipids in disorders of cornification. J Clin Invest 1981;68:1404-1410.
45. Marano RPC, Ortiz MA, Stradtmann O, Uxo M, Iglesias E. Ocular findings associated with congenital X-linked ichthyosis. Ann Ophthalmol 1991;23:167-173.
46. Chapdelaine A, MacDonald PC, Gonzalez O, Gurpide E, Vande Wiele RL, Lieberman S. Studies on the secretion and interconversion of the androgens. IV. Quantitative results in a normal man whose gonadal and adrenal function were altered experimentally. J Clin Endocrinol Metab 1965;25:1569-1579.
47. MacDonald PC, Chapdelaine A, Gonzalez O, Gurpide E, Vande Wiele RL, Lieberman S. Studies on the secretion and interconversion of the androgens. 3. Results obtained after the injection of several radioactive C-19 steroids, singly or as mixtures. J Clin Endocrinol Metab 1965;25:1557-1568.
48. Horton R, Tait JF. In vivo conversion of dehydroisoandrosterone to plasma androstenedione and testosterone in man. J Clin Endocrinol Metab 1967;27:79-88.
49. Lykkesfeldt G, Hoyer H, Ibsen HH, Brandrup F. Steroid sulphatase deficiency disease. Clin Genet 1985;28:231-237.
50. Unamuno P, Martin C, Fernandez E. X-linked ichthyosis and cryptorchidism. Dermatologica 1985;172:326-327.
51. Traupe H, Happle R. Mechanisms in the association of cryptochidism and X-linked recessive ichthyosis. Dermatologica 1986;172:327-328.
52. Pasqualini JR, Gelly C, Nguyen BL, Vella C. Importance of estrogen sulfates in breast cancer. J Steroid Biochem 1989;34:155-163.
53. Reed MJ, Purohit A. Sulphatase inhibitors. The rationale for the development of a new endocrine therapy. Rev Endocrine Related Cancer 1993;45:51-62.
54. Reed MJ, Purohit A, Howarth NM, Potter BVL. Steroid sulphatase inhibitors. A new endocrine therapy. Drugs Future 1994;19:673-680.
55. Pasqualini JR, Chetrite GS. Estrone sulfatase versus estrone sulfotransferase in human breast cancer: Potential clinical applications. J Steroid Biochem Mol Biol 1999;69:287-292.
56. Suzuki T, Moriya T, Ishida T, Kimura M, Ohuchi N, Sasano H. In situ production of estrogens in human breast carcinoma. Breast Cancer 2002;9:296-302.
57. Payne AH, Lawrence CC, Foster DL, Jaffe RB. Intranuclear binding of 17β-estradiol and estrone in female ovine pituitaries following incubation with estrone sulfate. J Biol Chem 1973;248:1598-1602.
58. Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada N. Elevated steroid sulfatase expression in breast cancers. J Steroid Biochem Mol Biol 2000;73:141-145.
59. Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M, Sasano H. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 2003;63:2762-2770.
60. Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K, Harada N. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res 1999;59:377-381.
61. Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Taguchi T, Tamaki Y, Noguchi S. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 2003;9:2288-2293.
62. Selcer KW, Jagannathan S, Rhodes ME, Li PK. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. J Steroid Biochem Mol Biol 1996;59:83-91.
63. Selcer KW, Hedge PV, Li PK. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N- alkanoyl tyramines. Cancer Res 1997;57:702-707.
64. Billich A, Nussbaumer P, Lehr P. Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: Inhibition by novel non-steroidal steroid sulfatase inhibitors. J Steroid Biochem Mol Biol 2000;73:225-235.
65. Purohit A, Hejaz HA, Walden L, MacCarthy-Morrogh L, Packham G, Potter BV, Reed MJ. The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 2000;85:584-589.
66. Raobaikady B, Purohit A, Chander SK, Woo LW, Leese MP, Potter BV, Reed MJ. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 2003;84:351-358.
67. Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 1995;63:106-111.
68. Purohit A, Woo LW, Potter BVL, Reed MJ. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 2000;60:3394-3396.
69. Peters RH, Chao WR, Sato B, Shigeno K, Zaveri NT, Tanabe M. Steroidal oxathiazine inhibitors of estrone sulfatase. Steroids 2003;68:97-110.
70. Le Bail JC, Allen K, Nicolas JC, Habrioux G. Dehydroepiandrosterone sulfate estrogenic action at its physiological plasma concentration in human breast cancer cell lines. Anticancer Res 1998;18:1683-1688.
71. Yamamoto T, Kitawaki J, Urabe M, Honjo H, Tamura T, Noguchi T, Okada H, Sasaki H, Tada A, Terashima Y. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 1993;44:463-468.
72. Watanabe T, Harada N, Sasaki H. Quantitative analysis of mRNA expression of estrone sulfatase in endometrial carcinoma and benign endometrium. Jikeikai Med J 2000;47:121-127.
73. Selcer KW, Kabler H, Sarap J, Xiao Z, Li PK. Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells. Steroids 2002;67:821-826.
74. 14C]dehydroepiandrosterone by human skin in vitro. Acta Med Acad Sci Hung 1970;27:95-102.
75. Voigt W, Sawaya ME, Hsia SL, Amthor C. Cutaneous production of potent androgens from dehydroepiandrosterone in adult women. IRSC Med Sci 1982;10:529-530.
76. Hoffmann R, Happle R. Current understanding of androgenetic alopecia. Part I. Etiopathogenesis. Eur J Dermatol 2000;10:319-327.
77. Hoffmann R, Rot A, Niiyama S, Billich A. Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. J Invest Dermatol 2001;117:1342-1348.
78. Billich A, Rot A, Lam C, Schmidt JB, Schuster I. Immunohistochemical localization of steroid sulfatase in acne lesions: Implications for the contribution of dehydroepiandrosterone sulfate to the pathogenesis of acne. Horm Res 2000;532:92-103.
79. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism. Basic research and clinical perspectives. J Invest Dermatol 2002;119:992-1007.
80. Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in central nervous system. Effects on cognition and emotion in animals and humans. Brain Res Rev 1999;30:264-288.
81. Li PK, Rhodes ME, Jagannathan S, Johnson DA. Reversal of scopolamine induced amnesia in rats by the steroids sulfatase inhibitor estrone-3-O- sulfamate. Cogn Brain Res 1995;2:251-254.
82. Li PK, Rhodes ME, Burke AM, Johnson DA. Memory enhancement mediated by the steroid sulfatase inhibitor (p-O-sulfamoyl)-N-tetradecanoyl tyramine. Life Sci 1996;60:45-51.
83. Rhodes ME, Li PK, Burke AM, Johnson DA. Enhanced plasma DHEAS, brain acetylcholine and memory mediated by steroid sulfatase inhibition. Brain Res 1997;773:28-32.
84. Johnson DA, Wu T, Li P, Maher TJ. The effect of steroid sulfatase inhibition on learning and spatial memory. Brain Res 2000;865:286-290.
85. Flood JF, Farr SA, Johnson DA, Li PK, Morley JE. Peripheral steroid sulfatase inhibition potentiates improvement of memory retention for hippocampally administered dehydroepiandrosterone sulfate but not pregnenolone sulfate. Psychoneuroendocrinology 1999;24:799-811.
86. Nicolas LB, Pinoteau W, Papot S, Routier S, Guillaumet G, Mortaud S. Aggressive behavior induced by the steroid sulfatase inhibitor COUMATE and by DHEAS in CBA/H mice. Brain Res 2001;922:216-222.
87. Daynes RA, Araneo BA, Dowell TA, Huang K, Dudley D. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990;171:979-996.
88. Sakura N, Nishimura S, Matsumoto T, Ohsaki M, Ogata T. Allergic disease as an association of steroid sulphatase deficiency. J Inher Metabol Dis 1997;20:807-810.
89. Suitters AJ, Shaw S, Wales MR, Porter JP, Leonard J, Woodger R, Brand H, Bodmer M, Foulkes R. Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulphatase. Immunology 1997;91:314-321.
90. Foulkes R, Shaw S, Suitters A. Immunological consequences of inhibiting dehydroepiandrosterone (DHEA) sulfatase in vivo. In: Rook GAW, Lightman S, editors. Steroid hormones and the T-cell cytokine profile. Berlin: Springer, Berlin; 1998. pp 135-162.
91. Shankaran R, Ameen M, Daniel WL, Davidson RG, Chang PL. Characterization of arylsulfatase C isoenzymes from human liver and placenta. Biochim Biophys Acta 1991;1078:251-257.
92. Wolff B, Billich A, Brunowsky W, Herzig G, Lindley I, Nussbaumer P, Pursch E, Rabeck C, Winkler G. Microtiter plate cellular assay for human steroid sulfatase with fluorescence readout. Anal Biochem 2003;318:276-284.
93. Nussbaumer P, Bilban M, Billich A. 4,4′-Benzophenone-O,O′- disulfamate, a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett 2002;12:2093-2095.
94. Nussbaumer P, Lehr P, Billich A. 2-Substituted 4-(thio)chromenone 6-O-sulfamates. Potent inhibitors of human steroid sulfatase. J Med Chem 2002;45:4310-4320.
95. Dibbelt L, Li PK, Pillai R, Knuppen R. Inhibition of human placental sterylsulfatase by synthetic analogs of estrone sulfate. J Steroid Biochem Mol Biol 1994;50:261-266.
96. Li PK, Pillai R, Dibbelt L. Estrone sulfate analogs as estrone sulfatase inhibitors. Steroids 1995;60:299-306.
97. Ciobanu LC, Boivin RP, Luu-The V, Poirier D. Synthesis and steroid sulphatase inhibitory activity of C19-and C21-steroidal derivatives bearing a benzyl-inhibiting group. Eur J Med Chem 2001;36:659-671.
98. Bilban M, Billich A, Auer M, Nussbaumer P. New fluorogenic substrate for the first continuous steroid sulfatase assay. Bioorg Med Chem Lett 2000;10:967-969.
99. a. Billich A, Bilban M, Meisner NC, Nussbaumer P, Neubauer A, Jäger S, Auer M. 2004. Confocal fluorescence detection expanded to UV-excitation: The first continuous fluorimetric assay of human steroid sulfatase in nanoliter volume. Assay Drug Dev Technol 2:1-10.
100. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens-Prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Molec Biol 1995;55:395-403.
101. Nussbaumer P, Winiski AP, Billich A. Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates, potent inhibitors of human steroid sulfatase. J Med Chem 2003;46:5091-5094.
102. Ciobanu LC, Boivin RP, Luu-The V, Poirier D. 3β-sulfamate derivatives of C19 and C21 steroids bearing a t-butylbenzyl or a benzyl group: Synthesis and evaluation as non-estrogenic and non-androgenic steroid sulfatase inhibitors. J Enzyme Inhib Med Chem 2003;18:15-26.
103. Li PK, Chu GH, Guo JP, Peters A, Selcer KW. Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids 1998;63:425-432.
104. Purohit A, Woo LWL, Singh A, Winterborn CJ, Potter BVL, Reed MJ. In vivo actvity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. Cancer Res 1996;56:4950-4955.
105. Shields-Botella J, Bonnet P, Duc I, Duranti E, Meschi S, Cardinali S, Prouheze P, Chaigneau AM, Duranti V, Gribaudo S, Riviere A, Mengual L, Carniato D, Cecchet L, Lafay J, Rondot B, Sandri J, Pascal JC, Delansorne R. In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity. J Steroid Biochem Mol Biol 2003;84:327-335.
106. Purohit A, Hejaz HA, Woo LW, van Strien AE, Potter BV, Reed MJ. Recent advances in the development of steroid sulphatase inhibitors. J Steroid Biochem Mol Biol 1999;69:227-238.
107. Fischer DS, Chander SK, Woo LW, Fenton JC, Purohit A, Reed MJ, Potter BV. Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol Biol 2003;84:343-349.
108. Poirier D, Ciobanu LC, Maltais R. Steroid sulfatase inhibitors. Exp Opin Ther Patents 1999;9:1083-1099.
109. Nussbaumer P, Billich A. Steroid sulfatase inhibitors. Exp Opin Ther Patents 2003;13:605-625.
110. Townsley JD, Scheel DA, Rubin EJ. Inhibition of steroid 3-sulfatase by endogenous steroids. A possible mechanism controlling placental estrogen synthesis from conjugated precursors. J Clin Endocrinol Metab 1970;31:670-678.
111. Farnsworth WE. Human prostatic dehydroepiandrosterone sulfate sulfatase. Steroids 1973;21:647-664.
112. Payne AH. Gonadal steroid sulfates and sulfatase. V. Human testicular steroid sulfatase. Partial characterization and possible regulation by free steroids. Biochim Biophys Acta 1972;258:473-483.
113. Townsley JD, Rubin EJ. Structure-activity correlations for steroid inhibition of human placental steroid 3-sulfatase. Res Steroids 1973;5:73-78.
114. Townsley JD. Further studies on the regulation of human placental steroid 3-sulfatase activity. Endocrinology 1973;93:172-181.
115. Evans TR, Rowlands MG, Jarman M, Coombes RC. Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma. J Steroid Biochem Mol Biol 1991;39:493-499.
116. Howarth NM, Cooper G, Purohit A, Duncan L, Reed MJ, Potter BVL. Phosphonates and thiophosphonates as sulfate surrogates. Synthesis of estrone 3-methylthio phosphonate, a potent inhibitor of estrone sulfatase. Bioorg Med Chem Lett 1993;3:313-318.
117. Duncan L, Purohit A, Howarth NM, Potter BVL, Reed MJ. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate. A potential therapeutic agent in breast cancer. Cancer Res 1993;53: 298-303.
118. Purohit A, Howarth NM, Potter BVL, Reed MJ. Inhibition of steroid sulfatase activity by steroidal methylthiophosphonates: Potential therapeutic agents in breast cancer. J Steroid Biochem Mol Biol 1994;48:523-527.
119. Li PK, Pillai R, Young BL, Bender WH, Martino DM, Lin FT. Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids 1993;58:106-111.
120. Selcer KW, Li PK. Estrogenicity, antiestrogenicity and estrone sulfatase inhibition of estrone-3-amine and estrone-3-thiol. J Steroid Biochem Mol Biol 1995;52:281-286.
121. Woo LW, Lightowler M, Purohit A, Reed MJ, Potter BV. Heteroatom- substituted analogues of the active-site directed inhibitor estra-1,3,5(10)- trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J Steroid Biochem Mol Biol 1996;57:79-88.
122. Anderson C, Freeman J, Lucas LH, Farley M, Dalhoumi H, Widlanski TS. Estrone sulfatase: Probing structural requirements for substrate and inhibitor recognition. Biochemistry 1997;36:2586-2594.
123. Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfonates as inhibitors of estrone sulfatase. Steroids 1997;62:346-350.
124. Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfamates: Potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 1994;37:219-221.
125. Horvath A, Nussbaumer P, Wolff-Winiski B, Billich A. 2-(1-Adamantyl)-4- (thio) chromenone-6-carboxylic acids: Potent reversible inhibitors of human steroid sulfatase. (submitted).
126. Poirier D, Boivin RP. 17α-alkyl- or 17α- substituted- 17β-estradiols. A new family of estrone-sulfatase inhibitors. Bioorg Med Chem Lett 1998;8:1891-1896.
127. Ciobanu LC, Boivin RP, Luu-The V, Labrie F, Poirier D. Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17α-benzyl (or 4-tertbutylbenzyl)estra-1,3,5(10)-trienes: Combination of two substituents at positions C3 and 17 of estradiol. J Med Chem 1999;42:2280-2286.
128. Boivin RP, Labrie F, Poirier D. 17Alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids 1999;64:825-833.
129. Boivin RP, Luu-The V, Lachance R, Labrie F, Poirier D. Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase. J Med Chem 2000;43:4465-4478.
130. Carlström K, Döberl A, Pousette A, Rannevik G, Wilking N. Inhibition of steroid sulfatase activity by danazol. Acta Obstet Gynecol Scand Suppl 1984;123:107-111.
131. Nguyen BL, Ferme I, Chetrite G, Pasqualini JR. Action of danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells. J Steroid Biochem Mol Biol 1993;46:17-23.
132. Santner SJ, Santen RJ. Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antiestrogens. J Steroid Biochem Mol Biol 1993;45:383-390.
133. Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J. Progestins and breast cancer. J Steroid Biochem Mol Biol 1998;65:225-235.
134. Pasqualini JR, Chetrite G, Nguyen BL, Maloche C, Delalonde L, Talbi M, Feinstein MC, Blacker C, Botella J, Paris J. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: A hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 1995;53:407-412.
135. Pasqualini JR, Maloche C, Maroni M, Chetrite G. Effect of the progestagen Promegestone (R-5020) on mRNA of the oestrone sulphatase in the MCF-7 human mammary cancer cells. Anticancer Res 1994; 14:1589-1593.
136. Chetrite G, Varin C, Delalonde L, Pasqualini JR. Effect of promegestone, tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on the oestrone sulphatase activity of human breast cancer cells. Anticancer Res 1993;13:931-934.
137. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17:135-140.
138. de Gooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: A compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183:55-62.
139. Purohit A, Malini B, Hooymans C, Newman SP. Inhibition of oestrone sulphatase activity by tibolone and its metabolites. Horm Metab Res 2002;34:1-6.
140. Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR. Effects of Org OD 14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anticancer Res 1999;19:261-267.
141. Yamamoto T, Yokata K, Urabe M, Kitawaki J, Honjo H. The inhibitory effect of medroxyprogesterone acetate on steroid sulfatase in human cancer cells. Endocrine-related Cancer 1996;3:337-340.
142. Pasqualini JR, Caubel P, Friedman AJ, Philippe JC, Chetrite GS. Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. Effect on sulfatase activity in comparison to medroxyprogesterone acetate. J Steroid Biochem Mol Biol 2003;84:193-198.
143. Chetrite G, Paris J, Botella J, Pasqualini JR. Effect of nomegestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells. J Steroid Biochem Mol Biol 1996;58:525-531.
144. Chetrite GS, Ebert C, Wright F, Philippe AC, Pasqualini JR. Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. J Steroid Biochem Mol Biol 1999;70:39-45.
145. Pasqualini JR, Nguyen BL. Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. independent human breast cancer cell lines. Breast Cancer Res Treat 1991;18:93-98.
146. Zhu BT, Kosh JW, Fu J, Cai MX, Xu S, Conney AH. Strong inhibition of estrone-3-sulfatase activity by pregnenolone 16alpha-carbonitrile but not by several analogs lacking a 16alpha-nitrile group. Steroids 2000;65:521-527.
147. Huang Z, Fasco MJ, Kaminsky LS. Inhibition of estrone sulfatase in human liver microsomes by quercetin and other flavonoids. J Steroid Biochem Mol Biol 1997;63:9-15.
148. Birnbock H, von Angerer E. Sulfate derivatives of 2-phenylindoles as novel steroid sulfatase inhibitors. An in vitro study on structure-activity- relationship. Biochem Pharmacol 1990;39:1709-1713.
149. Wong CK, Keung WM. Daidzein sulfoconjugates are potent inhibitors of sterol sulfatase (EC 3.1.6.2). Biochem Biophys Res Commun 1997;233:579-583.
150. Jütten P, Schumann W, Härtl A, Heinisch L, Grafe U, Werner W, Ulbricht H. A novel type of nonsteroidal estrone sulfatase inhibitors. Bioorg Med Chem Lett 2002;12:1339-1342.
151. Nussbaumer P, Horvath A, Lehr P, Wolff B, Geyl D, Billich A. Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase. Bioorg Med Chem Lett 2003;13:3673-3677.
152. Lee W, DeRome M, DeBear J, Noell S, Epstein D, Mahle C, DeCarr L, Woodruff K, Huang Z, Dumas J. Aryl piperazines: A new class of steroid sulfatase inhibitors for the treatment of hormone-dependent breast cancer. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003, MEDI-301.
153. Woo LWL, Howarth NM, Purohit A, Jejaz HAM, Reed MJ, Potter BVL. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med Chem 1998;41:1068-1083.
154. Woo LWL, Purohit A, Reed MJ, Potter BVL. Oestrone 3-O-(N-acetyl) sulphamate, a potential molecular probe of the active site of oestrone sulphatase. Bioorg Med Chem Lett 1997;7:3075-3080.
155. Purohit A, Vernon KA, Hummelinck AE, Woo LW, Hejaz HA, Potter BV, Reed MJ. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol 1998;64:269-275.
156. Tanabe M, Peters RH, Chao WR, Shigeno K. Preparation of estrone sulfamate inhibitors of estrone sulfatase. WO 9933858, Chem Abstr 1999;131:88083.
157. Reed MJ, Potter BVL, Hejaz H, Purohit A. Synthesis of halogenated sulfamate-, phosphonate-, thiophosphonate-, sulfonate- and sulphonamide estrone compounds as inhibitors of steroid sulfatase. WO 2001044268, Chem Abstr 2001;135:46353.
158. Potter BVL, Reed MJ. Preparation of estrogen 3-sulfamate derivatives for pharmaceutical use as steroid sulfatase inhibitors. WO 2002016393, Chem Abstr 2002;136:200349.
159. Potter BVL, Reed MJ. Preparation of thioether-sulfamate steroids as steroid sulfatase inhibitors and anti-cancer compounds. WO 2002016394, Chem Abstr 2002;136:216935.
160. Cushman M, He H-M, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicines binding site. J Med Chem 1995;38:2041-2049.
161. Hoogenboom LAP, De Haan L, Hooijerink D, Bor G, Murk AJ, Brouwer A. Estrogenic activity of estradiol and its metabolites in the ER-CALUX assay with human T47D breast cells. APMIS 2001;109: 101-107.
162. Fischer DS, Woo LWL, Mahon MF, Purohit A, Reed MJ, Potter BVL. D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg Med Chem 2003;11:1685-1700.
163. Reed MJ, Potter BVL. Synthesis and inhibitory activity of estratriene sulfamate derivatives as inhibitors of estrone sulfatase. WO 9927935, Chem Abstr 1999;131:19184.
164. Koizumi N, Takegawa S, Iwashita S, Kawachi T, Mieda M, Fujii T. Preparation of 3-substituted D-homo-1,3,5,(10)-estratriene derivatives. WO 9811124, Chem Abstr 1998;128:257603.
165. Ino Y, Amishiro N, Miyata M, Agatsuma T, Hayashi K, Takahashi T, Akinaga S, Murakata C. Preparation of estra-1,3,5(10)-triene derivatives as antitumor agents. WO 2001081364, Chem Abstr 2001;135:331582.
166. Li PK, Selcer KW. Preparation of steroid sulfatase inhibitors for the treatment of estrogen dependent illnesses. WO 9903876, Chem Abstr 1999;130:139509.
167. Li PK, Akinaga S, Murakata C. Preparation of sulfamoyloxyestratrienes for pharmaceutical use as estrone sulfatase inhibitors for the treatment of estrogen dependent illnesses. WO 2000043408, Chem Abstr 2000;133:105199.
168. Woo LWL, Purohit A, Reed MJ, Potter BVL. Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. J Med Chem 1996;39:1349-1351.
169. Ahmed S, Owen CP, James K, Sampson L, Patel CK. Review of estrone sulfatase and its inhibitors-An important new target against hormone dependent breast cancer. Curr Med Chem 2002;9:263-273.
170. Woo LL, Purohit A, Malini B, Reed MJ, Potter BV. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 2000;7:773-791.
171. Malini B, Purohit A, Ganeshapillai D, Woo LW, Potter BV, Reed MJ. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J Steroid Biochem Mol Biol 2000;75:253-258.
172. Billich A, Schreiner EP, Wolff-Winiski B. Benzoxa- and benzthiazoles and their pharmaceutical compositions and use as steroid sulfatase inhibitors. WO 2001036398, Chem Abstr 2001;134:366869.
173. Schreiner EP, Wolff B, Winiski AP, Billich A. 6-(2-Adamantan-2-ylidene- hydroxybenzoxazole)-O-sulfamate: A potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg Med Chem Lett 2003;13:4313-4316.
174. Li PK, Milano S, Kluth L, Rhodes ME. Synthesis and sulfatase inhibitory activities of nonsteroidal estrone sulfatase inhibitors. J Steroid Biochem Mol Biol 1996;59:41-48.
175. Chu GH, Milano S, Kluth L, Rhodes M, Boni R, Johnson DA, Li PK. Structure-activity relationship studies of the amide functionality in (p-O-sulfamoyl)-N-alkanoyl tyramines as estrone sulfatase inhibitors. Steroids 1997;62:530-535.
176. Kolli A, Chu HH, Rhodes ME, Inoue K, Selcer KW, Li PK. Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors. J Steroid Biochem Mol Biol 1999;68: 31-40.
177. Ahmed S, Owen CP, James K, Patel CK, Patel M. Acid dissociation constant, a potential physicochemical factor in the inhibition of the enzyme estrone sulfatase (ES). Bioorg Med Chem Lett 2001;11:899-902.
178. Ahmed S, James K, Owen CP, Patel CK, Patel M. Hydrophobicity, a physicochemical factor in the inhibition of the enzyme estrone sulfatase (ES). Bioorg Med Chem Lett 2001;11:2525-2528.
179. Ahmed S, James K, Owen CP, Patel CK. Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES). Bioorg Med Chem Lett 2002;12:1343-1346.
180. Ahmed S, James K, Owen CP. Inhibition of estrone sulfatase (ES) by derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett 2002;12:2391-2394.
181. Patel CK, Owen CP, Ahmed S. The design, synthesis, and in vitro biochemical evaluation of a series of esters of 4-[(aminosulfonyl)oxy]benzoate as novel and highly potent inhibitors of estrone sulfatase. Biochem Biophys Res Comm 2003;307:778-781.
182. Ciobanu LC, Luu-The V, Poirier D. Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors. J Steroid Biochem Mol Biol 2002;80:339-353.
183. Golob T, Liebl R, von Angerer E. Sulfamoyloxy-substituted 2-phenylindoles: Antiestrogen-based inhibitors of the steroid sulfatase in human breast cancer cells. Bioorg Med Chem 2002;10:3941-3953.
184. Chu G-H, Peters A, Selcer KW, Li PK. Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates. Bioorg Med Chem Lett 1999;9:141-144.
185. Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003;46:2197-2204.
186. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-189.
187. Ho YT, Purohit A, Vicker N, Newman SP, Robinson JJ, Leese MP, Ganeshapillai D, Woo LW, Potter BV, Reed MJ. Inhibition of carbonic anhydrase H by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun 2003;305:909-914.
188. Vicker N, Ho Y, Robinson J, Woo LL, Purohit A, Reed MJ, Potter BV. Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg Med Chem Lett 2003;13:863-865.
189. Barth A, Romer W, Oettel M. Influence of subchronic administration of oestrone-3-O-sulphamate on oestrone sulphatase activity in liver, spleen and white blood cells of ovariectomized rats. Arch Toxicol 2000;74:366-371.
190. Rabe T, Kiesel L, Radke G, Runnebaum B. New assay for steroid sulfatase (EC 3.1.6.2) and its application for studies of human placental and skin sulfatase. J Steroid Biochem 1984;20:627-632.
191. Purohit A, Froome VA, Wang DY, Potter BV, Reed MJ. Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate. J Steroid Biochem Mol Biol 1997;62:45-51.
192. Soliman HR, Dire D, Boudou P, Julien R, Launay JM, Brerault JL, Villette JM, Fiet J. Characterization of estrone sulfatase activity in human thrombocytes. J Steroid Biochem Mol Biol 1993;46:215-226.
193. Tamaki Y, Miyoshi Y, Kim SJ, Tanji Y, Taguchi T, Noguchi S. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. Expert Rev Anticancer Ther 2003;3:193-201.
194. Woo LW, Sutcliffe OB, Bubert C, Grasso A, Chander SK, Purohit A, Reed MJ, Potter BV. First dual aromatase-steroid sulfatase inhibitors. J Med Chem 2003;46:3193-3196.
195. Römer W, Oettel M, Schwarz S. Scavestrogen sulfamates: Correlation between estrone sulfatase inhibiting and antioxidant effects. Can J Physiol Pharmacol 1998;76:99-109.
196. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59:551-555.
197. Harper ME, Pike A, Peeling WB. Steroids of adrenal origin metabolized by human prostatic tissue in vivo and in vitro. J Endocrinol 1974;60:117-125.
198. Schwarz S, Elger W. Estrogen sulfamates, a novel approach to oral contraception and hormone replacement therapy. Drugs Future 1996;21:49-61.
199. Elger W, Palme HJ, Schwarz S. Novel oestrogen sulphamates: A new approach to oral hormone therapy. Exp Opinion Invest Drugs 1998;7:575-589.
200. Hejaz HAM, Purohit A, Mahon MF, Reed MJ, Potter BVL. Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)- estratriene. X-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)- estratriene. J Med Chem 1999;42:3188-3192.
201. Elger W, Barth A, Hedden A, Reddersen G, Ritter P, Schneider B, Zuchner J, Krahl E, Muller K, Oettel M, Schwarz S. Estrogen sulfamates: A new approach to oral estrogen therapy. Reprod Fertil Dev 2001; 13:297-305.
202. Sahm UG, Williams GJ, Purohit A, Hidalgo Aragones MI, Parish D, Reed MJ, Potter BVL, Pouton CW. Development of an oral formulation for oestrone 3-O-sulphamate, a potent sulphatase inhibitor. Pharm Sci 1996;2:17-20.
203. Hidalgo Aragones MI, Purohit A, Parish D, Sahm UG, Pouton CW, Potter BV, Reed MJ. Pharmacokinetics of oestrone-3-O-sulphamate. J Steroid Biochem Mol Biol 1996;58:611-617.